Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication

References

• Mohd HanafiahKGroegerJFlaxmanADWiersmaSTGlobal epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalenceHepatology20135741333134223172780
   PubMed Web of Science ®Google Scholar
• DabbousehNMJensenDMFuture therapies for chronic hepatitis CNat Rev Gastroenterol Hepatol20131052687623419289
   PubMedGoogle Scholar
• ZeuzemSAndreonePPolSREALIZE Study TeamTelaprevir for retreatment of HCV infectionN Engl J Med2011364252417242821696308
   PubMed Web of Science ®Google Scholar
• Kim doYAhnSHHanKHEmerging therapies for hepatitis CGut Liver20148547147925228970
   PubMedGoogle Scholar
• SchinaziRHalfonPMarcellinPAsselahTHCV direct-acting antiviral agents: the best interferon-free combinationsLiver Int201434Suppl 1697824373081
   PubMed Web of Science ®Google Scholar
• LenzOVijgenLBerkeJMVirologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202)J Hepatol201358344545123142061
   PubMedGoogle Scholar
• PovedaEWylesDLMenaAPedreiraJDCastro-IglesiasACachayEUpdate on hepatitis C virus resistance to direct-acting antiviral agentsAntiviral Res201410818119124911972
   PubMed Web of Science ®Google Scholar
• XiaoFFofanaIHeydmannLHepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agentsPLoS Pathog2014105e100412824830295
   PubMed Web of Science ®Google Scholar
• GeorgelPSchusterCZeiselMBVirus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategiesTrends Mol Med201016627728620537953
   PubMed Web of Science ®Google Scholar
• ZeiselMBLupbergerJFofanaIBaumertTFHost-targeting agents for prevention and treatment of chronic hepatitis C – perspectives and challengesJ Hepatol201358237538423041307
   PubMed Web of Science ®Google Scholar
• GuedjJYuJLeviMModeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patientsHepatology20145951706171424375768
   PubMedGoogle Scholar
• ChatterjiUGarcia-RiveraJABaughJThe combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistanceAntimicrob Agents Chemother20145863327333424687498
   PubMed Web of Science ®Google Scholar
• KaulAStaufferSBergerCEssential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kineticsPLoS Pathog200958e100054619680534
   PubMed Web of Science ®Google Scholar
• LiuZYangFRobothamJMTangHCritical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complexJ Virol200983136554656519386705
   PubMed Web of Science ®Google Scholar
• YangFRobothamJMGriseHA major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approachPLoS Pathog201069e100111820886100
   PubMedGoogle Scholar
• Garcia-Saenz-de-SiciliaMMukherjeeSThe adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practiceExpert Rev Clin Pharmacol20125558759323121280
   PubMed Web of Science ®Google Scholar
• FauldsDGoaKLBenfieldPCyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disordersDrugs45695310407691501
   PubMedGoogle Scholar
• BobadillaNAGambaGNew insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosteroneAm J Physiol Renal Physiol20072931F2F917429034
   PubMedGoogle Scholar
• WendtAAdhouteXCastellaniPChronic hepatitis C: future treatmentClin Pharmacol2014611724470777
   PubMedGoogle Scholar
• DanhierFAnsorenaESilvaJMCocoRLe BretonAPréatVPLGA-based nanoparticles: an overview of biomedical applicationsJ Control Release2012161250552222353619
   PubMed Web of Science ®Google Scholar
• JaiswalJGuptaSKKreuterJPreparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation processJ Control Release200496116917815063039
   PubMed Web of Science ®Google Scholar
• AksungurPDemirbilekMDenkbaşEBVandervoortJLudwigAUnlüNDevelopment and characterization of cyclosporine A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studiesJ Control Release2011151328629421241752
   PubMed Web of Science ®Google Scholar
• ItaliaJLBhattDKBhardwajVTikooKKumarMNPLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune NeoralJ Control Release2007119219720617399839
   PubMed Web of Science ®Google Scholar
• VasirJKLabhasetwarVBiodegradable nanoparticles for cytosolic delivery of therapeuticsAdv Drug Deliv Rev200759871872817683826
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
   PubMed Web of Science ®Google Scholar
• JohnstoneTCKulakNPridgenEMFarokhzadOCLangerRLippardSJNanoparticle encapsulation of mitaplatin and the effect thereof on in vivo propertiesACS Nano2013775675568323697579
   PubMedGoogle Scholar
• GrafNBielenbergDRKolishettiNα(V)β(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrugACS Nano2012654530453922584163
   PubMed Web of Science ®Google Scholar
• PengXHWangYHuangDTargeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticlesACS Nano20115129480949322032622
   PubMed Web of Science ®Google Scholar
• LeeMYYangJAJungHSHyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infectionACS Nano20126119522953123092111
   PubMed Web of Science ®Google Scholar
• RobertsonRTBarattaJLHaynesSMLongmuirKJLiposomes incorporating a Plasmodium amino acid sequence target heparan sulfate binding sites in liverJ Pharm Sci20089783257327317932963
   PubMedGoogle Scholar
• KoutsoudakisGKaulASteinmannECharacterization of the early steps of hepatitis C virus infection by using luciferase reporter virusesJ Virol200680115308532016699011
   PubMed Web of Science ®Google Scholar
• KumthipKChusriPJilgNHepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signalingJ Virol201286168581859122674974
   PubMed Web of Science ®Google Scholar
• SpivakMYBubnovRVYemetsIMLazarenkoLMTymoshokNOUlbergZRGold nanoparticles – the theranostic challenge for PPPM: nanocardiology applicationEPMA J2013411823800174
   PubMedGoogle Scholar
• KriegerNLohmannVBartenschlagerREnhancement of hepatitis C virus RNA replication by cell culture-adaptive mutationsJ Virol200175104614462411312331
   PubMed Web of Science ®Google Scholar
• ChatterjiULimPBobardtMDHCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitorsJ Hepatol2010531505620451281
   PubMedGoogle Scholar
• SarrazinCHézodeCZeuzemSPawlotskyJMAntiviral strategies in hepatitis C virus infectionJ Hepatol201256Suppl 1S88S10022300469
   PubMed Web of Science ®Google Scholar
• GrefRLuckMQuellecP‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorptionColloids Surf B Biointerfaces2000183–430131310915952
   PubMed Web of Science ®Google Scholar
• LiYPZhouZHPeiYYZhangXYGuZHYuanWFPEGylated polycyanoacrylate nanoparticles as salvicine carriers: synthesis, preparation, and in vitro characterizationActa Pharmacol Sin200122764565011749831
   PubMedGoogle Scholar
• FischerGGallayPHopkinsSCyclophilin inhibitors for the treatment of HCV infectionCurr Opin Investig Drugs2010118911918
   Google Scholar
• AzziJTangLMooreRPolylactide-cyclosporin A nanoparticles for targeted immunosuppressionFASEB J201024103927393820547662
   PubMed Web of Science ®Google Scholar
• TangLAzziJKwonMImmunosuppressive activity of size-controlled PEG-PLGA nanoparticles containing encapsulated cyclosporine AJ Transplant2012201289614122545201
   PubMedGoogle Scholar
• HopkinsSGallayPCyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infectionViruses20124112558257723202494
   PubMedGoogle Scholar
• IshiiNWatashiKHishikiTDiverse effects of cyclosporine on hepatitis C virus strain replicationJ Virol20068094510452016611911
   PubMedGoogle Scholar